Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2018
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms PROCEED
- 31 Jul 2017 Status changed from not yet recruiting to recruiting.
- 07 Jun 2017 Planned initiation date changed from 1 May 2017 to 1 Jul 2017.
- 09 Mar 2017 New trial record